Natural History of Treated Neurocysticercosis and Long-Term Outcomes
National Institute of Allergy and Infectious Diseases (NIAID) · NCT00001205
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 3–99 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 500
- US sites recruiting
- 1
- Study start
- October 7, 1985
- Record last updated
- October 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care....
Conditions: Cysticercosis; Neurocysticercosis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- INCLUSION CRITERIA:
Arms 1-5 (NCC):
- Aged 3 years and older.
- Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document.
- Patients with proven or likely NCC
Arm 6 (Endemic Exposures):
- Patient with epidemiologic history compatible with possible exposure to NCC
- Aged 18 years and older.
EXCLUSION CRITERIA
Not applicable
Recruiting US locations
National Institutes of Health Clinical Center
Bethesda, MD 20892
Study contacts (from the official record)
- Perla M Adames Castillo, R.N. · (301) 402-8495 · perla.adamescastillo@nih.gov
- Elise M O'Connell, M.D. · (301) 761-5413 · oconnellem@mail.nih.gov
Similar studies in Maryland
All neurology studies in Maryland →- RecruitingHealthy volunteersPhase 1
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
Suninflam Inc
- Location
- Bathesda, MD + 9 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
First-in-Human Single and Multiple Dose of HL-400
Highlightll Pharmaceutical (USA) LLC
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
PRG Science & Technology Co., Ltd.
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
National Institute of Mental Health (NIMH)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 50–100